polypoidal choroidal vasculopathy (PCV): Definition, Uses, and Clinical Overview

polypoidal choroidal vasculopathy (PCV) Introduction (What it is)

polypoidal choroidal vasculopathy (PCV) is a retinal condition involving abnormal blood vessels beneath the retina.
It can cause fluid leakage or bleeding that may blur or distort central vision.
It is most commonly discussed in the context of macular disease and can resemble “wet” age-related macular degeneration (AMD).
In eye clinics, it is identified with specialized retinal imaging and managed with medical and/or laser-based therapies.

Why polypoidal choroidal vasculopathy (PCV) used (Purpose / benefits)

polypoidal choroidal vasculopathy (PCV) is not a tool or device; it is a diagnosis. The “purpose” of recognizing PCV is to accurately label a specific cause of macular leakage and bleeding so clinicians can select appropriate testing, monitoring, and treatment options.

Key benefits of correctly identifying PCV include:

• Clarifying the cause of symptoms such as blurred central vision, distortion (metamorphopsia), or a dark/gray spot (scotoma).
• Guiding imaging choices, because PCV may be better characterized with certain angiography methods than typical macular neovascularization.
• Supporting treatment planning, since some eyes with PCV respond differently to various therapies than other forms of macular neovascular disease.
• Improving communication between clinicians and patients by distinguishing PCV from similar-appearing conditions (for example, neovascular AMD without polypoidal lesions).

In practical terms, identifying PCV helps match the right level of monitoring and intervention to the underlying problem: abnormal choroidal/retinal vascular changes that can leak or bleed under the macula (the central retina responsible for detailed vision).

Indications (When ophthalmologists or optometrists use it)

Clinicians consider polypoidal choroidal vasculopathy (PCV) as part of the differential diagnosis when findings suggest a particular pattern of subretinal vascular disease, especially in the macula. Common scenarios include:

• New or recurrent subretinal fluid or subretinal pigment epithelium (RPE) fluid on optical coherence tomography (OCT)
• Serous or hemorrhagic pigment epithelial detachment (PED) (a “blister-like” elevation of the RPE)
• Subretinal hemorrhage (bleeding beneath the retina), especially when disproportionate to other exam findings
• Suspected neovascular (“wet”) macular degeneration with atypical imaging features
• Persistent or recurrent exudation (leakage) despite prior therapy, where clarifying the subtype of macular neovascularization may matter
• Macular findings associated with a thickened choroid or “pachychoroid” features (varies by clinician and case)
• Unexplained central vision symptoms with subtle retinal exam changes that warrant advanced imaging

Contraindications / when it’s NOT ideal

Because polypoidal choroidal vasculopathy (PCV) is a diagnosis rather than a treatment, it is not “contraindicated” in the way a medication or surgery can be. However, there are situations where labeling a case as PCV may be less appropriate, or where PCV-focused testing/treatment approaches may not be ideal.

Situations where another diagnosis may be more likely, or where additional evaluation is needed, include:

• Findings better explained by diabetic macular edema, retinal vein occlusion, or inflammatory chorioretinal disease
• Macular fluid patterns more consistent with central serous chorioretinopathy without evidence of polypoidal lesions (varies by clinician and case)
• Hemorrhage driven primarily by retinal tears, trauma, or other non-macular causes
• Imaging that supports a different type of macular neovascularization without polyp-like dilations

Situations where certain common PCV-related tests or interventions may be limited:

• Dye-based angiography limitations, such as allergy history or medical factors that make fluorescein angiography (FA) or indocyanine green angiography (ICGA) less suitable (determined by the treating team)
• Laser- or phototherapy limitations, where lesion location or ocular factors make thermal laser or photodynamic therapy (PDT) less appropriate (varies by clinician and case)
• Coexisting eye conditions that complicate interpretation or outcomes, such as advanced scarring, severe cataract limiting imaging quality, or significant macular atrophy

How it works (Mechanism / physiology)

polypoidal choroidal vasculopathy (PCV) involves abnormal vessels in the choroid, the vascular layer beneath the retina. These abnormal vessels can form a branching vascular network with polyp-like aneurysmal dilations (the “polypoidal” component). The lesions are typically located beneath the retinal pigment epithelium (RPE), a supportive cell layer critical for retinal health.

High-level physiology and anatomy:

• Choroid: Supplies oxygen and nutrients to the outer retina. Changes in choroidal circulation are central to PCV.
• RPE (retinal pigment epithelium): Acts as a barrier and pump. When fluid or blood accumulates under or above the RPE, vision can be affected.
• Macula: Central retina responsible for reading and recognizing faces; fluid or blood here can cause noticeable symptoms.

What PCV does in the eye:

• Abnormal choroidal vessels may leak fluid, leading to subretinal fluid and blurred or distorted central vision.
• Fragile vascular structures may bleed, causing subretinal hemorrhage or bleeding under the RPE.
• Repeated leakage/bleeding can contribute to scarring or long-term macular damage in some cases.

Onset, duration, and reversibility:

• PCV often behaves as a chronic condition with periods of activity and quiescence (quiet phases), though presentations vary widely.
• Some findings (like fluid) may improve when the vascular activity is controlled; other changes (like scarring) may be less reversible.
• “Duration” is not a set timeframe; it varies by clinician and case, lesion characteristics, and comorbidities.

polypoidal choroidal vasculopathy (PCV) Procedure overview (How it’s applied)

polypoidal choroidal vasculopathy (PCV) is not a single procedure. In practice, it is identified through an exam and imaging workup, and then managed using an individualized plan that may include medications delivered to the eye and/or laser-based therapies. A typical workflow is outlined below.

Evaluation / exam

• Symptom review (for example, distortion or reduced central vision)
• Visual acuity testing and dilated retinal examination
• OCT imaging to assess retinal fluid, PEDs, and macular structure

Preparation

• Selection of additional imaging when needed to clarify the diagnosis
• Discussion of potential benefits/limitations of imaging and therapy options (general counseling varies by clinic)

Intervention / testing

• OCT angiography (OCT-A): Non-dye imaging that can show abnormal blood flow patterns in and under the retina (may not replace all dye studies).
• Fluorescein angiography (FA): Dye test highlighting retinal circulation and leakage patterns.
• Indocyanine green angiography (ICGA): Dye test that better visualizes choroidal circulation and is commonly used to identify polypoidal lesions and branching networks.

Immediate checks

• Review of imaging for signs of active leakage/bleeding and risk features
• Baseline documentation of lesion location relative to the fovea (the most sensitive central point of the macula)

Follow-up

• Repeat OCT (and sometimes repeat angiography) to track fluid, bleeding, and response
• Ongoing monitoring intervals and treatment frequency vary by clinician and case

Types / variations

PCV is described using clinical and imaging patterns rather than a single universal subtype system. Commonly discussed variations include:

• Location-based patterns
• Macular PCV: Lesions centered in the macula; often affects central vision.

• Peripapillary PCV: Lesions near the optic nerve; symptoms and risks can differ (varies by case).

• Lesion composition on imaging

• PCV with a prominent branching vascular network plus polypoidal dilations

• PCV where polypoidal components are easier to see than the network (or vice versa), depending on imaging method and disease stage

• Clinical behavior

• Exudative-dominant PCV: More fluid leakage (swelling) than bleeding.

• Hemorrhagic-dominant PCV: More bleeding events, sometimes with large subretinal hemorrhage.

• Relationship to broader macular disease categories

• PCV is often considered a subtype within the spectrum of macular neovascular disease and may overlap with neovascular AMD features.

• Some cases are discussed in the context of the pachychoroid spectrum (thicker choroid and related findings), though classification varies by clinician and case.

• Management approach variations

• Medication-only strategies (commonly anti-VEGF injections)
• Combination approaches (for example, anti-VEGF plus PDT), depending on lesion features, access, and clinician preference

Pros and cons

Pros:

• Can provide a more specific diagnosis than “wet macular degeneration” alone in appropriate cases
• Helps clinicians choose targeted imaging (especially choroid-focused studies)
• Supports treatment planning when multiple options exist (medication, laser-based therapy, or combination)
• Creates a shared framework for discussing risk of leakage and bleeding
• Imaging follow-up can be objective and trackable (for example, OCT fluid measurements)

Cons:

• Can look similar to other macular diseases, so misclassification is possible without adequate imaging
• Some definitive imaging methods may require dye angiography, which is not suitable for every patient
• Disease activity may be intermittent, requiring ongoing monitoring even when symptoms improve
• Treatment response can be variable, and more than one treatment approach may be considered over time
• Recurrence of fluid or bleeding can occur, and long-term outcomes depend on multiple factors (varies by clinician and case)

Aftercare & longevity

Because PCV is a chronic retinal condition, “aftercare” usually means ongoing monitoring and, when indicated, repeat therapy to control leakage or bleeding. Longevity of results is not a single number and depends on several interacting factors:

• Baseline severity and lesion features: Location near the fovea, size of hemorrhage, and presence of scarring can influence visual outcomes.
• Type and consistency of follow-up: Imaging-based monitoring (often OCT) helps detect recurrent fluid early; schedules vary by clinician and case.
• Treatment strategy used: Some approaches aim to reduce fluid, others target the polypoidal lesions more directly, and combination strategies are sometimes used (varies by clinician and case).
• Coexisting eye conditions: Cataract, glaucoma, diabetic eye disease, or macular atrophy can affect vision independently of PCV.
• General health factors and medications: Systemic health can influence ocular vascular conditions, and clinicians may consider the overall medical context when planning tests or therapies.

In many practices, outcomes are tracked through changes in symptoms, visual acuity, OCT fluid levels, and (when used) angiography findings showing lesion activity.

Alternatives / comparisons

Because PCV overlaps with other macular conditions, alternatives usually refer to alternative diagnoses to consider and alternative management strategies once macular neovascular disease is confirmed.

High-level comparisons:

• PCV vs typical neovascular (“wet”) AMD
• Both can cause macular fluid and bleeding.
• PCV specifically involves polyp-like choroidal vascular dilations and may be better characterized with ICGA.

• Treatment options overlap substantially (often anti-VEGF therapy), but the choice to add other modalities can differ (varies by clinician and case).

• Observation/monitoring vs active treatment

• Monitoring may be considered in selected situations where there is no threatening fluid/bleeding or when risks outweigh benefits (varies by clinician and case).

• Active treatment is often used when there is evidence of ongoing leakage, bleeding, or vision impact, but specific decisions are individualized.

• Anti-VEGF injections vs photodynamic therapy (PDT) vs thermal laser

• Anti-VEGF therapy targets vascular signaling that promotes abnormal vessel growth and leakage; it is widely used across macular neovascular diseases.
• PDT is a laser-activated medication approach aimed at abnormal choroidal vessels and is sometimes used in PCV management depending on lesion characteristics and availability.

• Thermal laser may be considered for select extrafoveal lesions in some contexts, but is not appropriate for many macular lesions due to risk of damaging central retina (varies by clinician and case).

• OCT-A vs dye angiography

• OCT-A is non-dye and convenient but may not show all lesion components in every case.
• FA/ICGA provide dynamic dye leakage and choroidal detail; ICGA is often highlighted for PCV identification, but requires intravenous dye.

polypoidal choroidal vasculopathy (PCV) Common questions (FAQ)

Q: Is polypoidal choroidal vasculopathy (PCV) the same as wet AMD?
PCV is often discussed as a subtype within the broader category of macular neovascular disease and can resemble wet AMD. Some clinicians consider it a variant of neovascular AMD, while others emphasize it as a distinct entity based on choroidal vascular features. The distinction matters mainly because imaging findings and management strategies may differ.

Q: What symptoms can PCV cause?
PCV can cause blurred or distorted central vision, difficulty reading, or a dark/gray spot in the center of vision. Some people notice sudden changes when bleeding occurs. Symptoms can also be mild early on, which is why imaging is important.

Q: How is PCV diagnosed?
Diagnosis typically combines a dilated retinal exam with retinal imaging such as OCT. When PCV is suspected, clinicians may use angiography—especially indocyanine green angiography (ICGA)—to visualize polypoidal lesions and associated vascular networks. The exact imaging set depends on the clinic and the case.

Q: Are the tests or treatments painful?
Most retinal imaging is not painful, though bright lights and dilation can be uncomfortable. Intravitreal injections (when used) are typically performed with anesthetic steps to reduce discomfort; experiences vary. Dye angiography involves an IV injection and can cause temporary sensations such as warmth or nausea in some individuals (varies by person).

Q: How long do results last after treatment?
There is no single duration because PCV activity can wax and wane. Some eyes show longer quiet periods after therapy, while others require repeated treatments or combination approaches. Longevity depends on lesion features, treatment type, and follow-up findings (varies by clinician and case).

Q: Is polypoidal choroidal vasculopathy (PCV) considered “safe” to treat?
Treatments used for PCV are commonly used in retinal practice, but all medical procedures have potential risks and benefits. Safety considerations depend on the therapy (injection vs PDT vs laser), the eye’s anatomy, and overall health. Clinicians weigh these factors when selecting an approach.

Q: Will I be able to drive or use screens after visits?
After dilating eye drops, vision is often blurred and light-sensitive for several hours, which can affect driving. Screen use is usually possible but may be uncomfortable immediately after dilation or bright-light testing. Any restrictions depend on what tests or procedures were done that day.

Q: Does PCV affect one eye or both eyes?
PCV can present in one eye, but the other eye may have related changes or develop disease later. Whether both eyes are involved depends on individual risk factors and underlying retinal/choroidal characteristics. Monitoring practices vary by clinician and case.

Q: What is the cost range for diagnosis and treatment?
Costs vary widely based on the country, insurance coverage, clinic setting, and which tests or treatments are used. Advanced imaging (especially dye angiography) and recurring therapies can change overall cost. A clinic typically provides estimates based on the planned workup and therapy schedule.

Q: Can PCV come back after it improves?
Recurrence of fluid or bleeding can happen because PCV is often chronic and may reactivate. Follow-up imaging is used to detect changes early, even when symptoms are stable. The likelihood and timing of recurrence vary by clinician and case.